NASDAQ:PAHC - Phibro Animal Health Stock Price, Forecast & News

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health announced a quarterly dividend on Monday, February 3rd. Shareholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share on Wednesday, March 25th. This represents a $0.48 annualized dividend and a yield of 1.78%. The ex-dividend date of this dividend is Tuesday, March 3rd. View Phibro Animal Health's Dividend History.

Phibro Animal Health Corp (NASDAQ:PAHC) released its quarterly earnings results on Monday, February, 3rd. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.06. The business had revenue of $214 million for the quarter, compared to analyst estimates of $218.87 million. Phibro Animal Health had a return on equity of 23.94% and a net margin of 4.67%. The firm's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm earned $0.41 earnings per share. View Phibro Animal Health's Earnings History.

Phibro Animal Health is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Phibro Animal Health.

Phibro Animal Health issued an update on its FY20 earnings guidance on Monday, February, 3rd. The company provided earnings per share guidance of $1.15-1.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.11. The company issued revenue guidance of $812-828 million, compared to the consensus revenue estimate of $838.36 million.

6 brokers have issued 1-year price targets for Phibro Animal Health's stock. Their forecasts range from $18.00 to $30.00. On average, they expect Phibro Animal Health's stock price to reach $25.20 in the next twelve months. This suggests that the stock has a possible downside of 6.7%. View Analyst Price Targets for Phibro Animal Health.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 1 sell rating and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.

News headlines about PAHC stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Phibro Animal Health earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Phibro Animal Health.

Some companies that are related to Phibro Animal Health include BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Emergent Biosolutions (EBS) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Zoetis (ZTS), Booking (BKNG), Banco Bradesco (BBD) and Gilead Sciences (GILD).

Phibro Animal Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (2.68%), Principal Financial Group Inc. (2.35%), Renaissance Technologies LLC (2.07%), State Street Corp (1.71%), Cove Street Capital LLC (1.47%) and Eagle Asset Management Inc. (1.16%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran and Jack Bendheim. View Institutional Ownership Trends for Phibro Animal Health.

PAHC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Ceredex Value Advisors LLC, Acadian Asset Management LLC, Oxford Asset Management LLP, Bank of New York Mellon Corp, Goldman Sachs Group Inc., AQR Capital Management LLC and Credit Suisse AG. View Insider Buying and Selling for Phibro Animal Health.

PAHC stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Eagle Asset Management Inc., Madison Asset Management LLC, Heartland Advisors Inc., Martingale Asset Management L P, Raymond James & Associates, Renaissance Technologies LLC and South Dakota Investment Council. View Insider Buying and Selling for Phibro Animal Health.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAHC stock can currently be purchased for approximately $27.02.

Phibro Animal Health has a market capitalization of $1.09 billion and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.View Additional Information About Phibro Animal Health.

The official website for Phibro Animal Health is http://www.pahc.com/.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]